Cargando…

Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021

Detalles Bibliográficos
Autores principales:	Grannis, Shaun J., Rowley, Elizabeth A., Ong, Toan C., Stenehjem, Edward, Klein, Nicola P., DeSilva, Malini B., Naleway, Allison L., Natarajan, Karthik, Thompson, Mark G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2021
Materias:	Full Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445373/ https://www.ncbi.nlm.nih.gov/pubmed/34529642 http://dx.doi.org/10.15585/mmwr.mm7037e2

Ejemplares similares

Genetic emergence of B.1.617.2 in COVID-19
por: Kirola, L.
Publicado: (2021)

Effectiveness of COVID-19 Vaccines at Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompromised Adults: An Observational Study of Real-World Data Across 10 US States from August-December 2021
por: Embi, Peter J., et al.
Publicado: (2023)

Analysis of the Delta Variant B.1.617.2 COVID-19
por: Shiehzadegan, Shayan, et al.
Publicado: (2021)

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
por: Tenforde, Mark W., et al.
Publicado: (2022)

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
por: Tenforde, Mark W., et al.
Publicado: (2023)

Impact of different COVID-19 encounter definitions on antibiotic prescribing rates in urgent care
por: Onguti, Sharon, et al.
Publicado: (2022)

The efficacy of COVID-19 vaccines against the B.1.617.2 (delta) variant
por: Cai, Changjing, et al.
Publicado: (2021)

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
por: Lopez Bernal, Jamie, et al.
Publicado: (2021)

Increasing severity of COVID-19 in pregnancy with Delta (B.1.617.2) variant surge
por: Adhikari, Emily H., et al.
Publicado: (2022)

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
por: Thompson, Mark G., et al.
Publicado: (2022)

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
por: Seppälä, Elina, et al.
Publicado: (2021)

Chest CT features of children infected by B.1.617.2 (Delta) variant of COVID-19
por: Cheng, Qi-Rui, et al.
Publicado: (2021)

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
por: Harder, Thomas, et al.
Publicado: (2021)

Analysis of clinical characteristics of 66 pediatric patients with B.1.617.2 (Delta) variant of COVID-19
por: Hao, Jing, et al.
Publicado: (2022)

Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis
por: Mahumud, Rashidul Alam, et al.
Publicado: (2022)

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
por: Ferdinands, Jill M., et al.
Publicado: (2022)

Impact of inactivated COVID-19 vaccines on viral shedding in B.1.617.2 (Delta) variant-infected patients
por: Hu, Zhiliang, et al.
Publicado: (2022)

Histopathological Lung Findings in COVID-19 B.1.617.2 SARS-CoV-2 Delta Variant
por: Jeican, Ionuț Isaia, et al.
Publicado: (2023)

Impact of inactivated COVID-19 vaccines on lung injury in B.1.617.2 (Delta) variant-infected patients
por: Lai, Miao, et al.
Publicado: (2023)

Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023
por: Link-Gelles, Ruth, et al.
Publicado: (2023)

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland
por: Rzymski, Piotr, et al.
Publicado: (2022)

Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
por: Wang, Stephen Y, et al.
Publicado: (2022)

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
por: Klein, Nicola P., et al.
Publicado: (2022)

Transmission Dynamics of an Outbreak of the COVID-19 Delta Variant B.1.617.2 — Guangdong Province, China, May–June 2021
por: Zhang, Meng, et al.
Publicado: (2021)

Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022
por: Natarajan, Karthik, et al.
Publicado: (2022)

Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance — COVID-NET, 14 States, January–August 2021
por: Taylor, Christopher A., et al.
Publicado: (2021)

Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2022)

Vaccine effectiveness against the B.1.617.2 in the intensive care unit
por: Koc, Ibrahim, et al.
Publicado: (2023)

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
por: Bierle, Dennis M., et al.
Publicado: (2021)

Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant–infected patients in Jiangsu, China
por: Hu, Zhiliang, et al.
Publicado: (2022)

Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies
por: Pormohammad, Ali, et al.
Publicado: (2021)

Effect of COVID-19 Delta (B.1.617.2) and Omicron (B.1.1.529) surges on emergency medicine physician compassion
por: Bowling, John M., et al.
Publicado: (2022)

Genome Sequences of the Delta Variant (B.1.617.2) and the Kappa Variant (B.1.617.1) Detected in Morocco
por: Melloul, Marouane, et al.
Publicado: (2021)

Genome Characterization of the First Outbreak of COVID-19 Delta Variant B.1.617.2 — Guangzhou City, Guangdong Province, China, May 2021
por: Li, Zhencui, et al.
Publicado: (2021)

Changing Features of Liver Injury in COVID-19 Patients: Impact of Infection with the SARS-CoV-2 Delta (B.1.617.2) Variants
por: Choi, Chang Wan, et al.
Publicado: (2022)

Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers
por: Kemp, Steven A., et al.
Publicado: (2022)

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021
por: Fowlkes, Ashley, et al.
Publicado: (2021)

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021
por: Embi, Peter J., et al.
Publicado: (2021)

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021
por: Embi, Peter J., et al.
Publicado: (2022)

Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study
por: Allen, Hester, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p5kemodvopha0clt0qiupk8028